Yahoo! Inc. (NASDAQ:YHOO) declared that it is working with Google Inc. (GOOG) on a test that would use Google’s search results and advertisements on its site. If successful, the trial could result in a larger search deal between the companies. Yahoo confirmed the initiative, while declining to comment further. The company said in a statement, “As we work to create the absolute best experiences for Yahoo users, from time to time, we run small tests with a variety of partners including search providers. “There is nothing further to share at this time.” Yahoo’s search is currently powered by Microsoft Corp.’s Bing. The two companies renegotiated their agreement earlier this year, giving Yahoo more freedom over how it makes money from ads on search. Google operates the world’s biggest search engine. Yahoo! Inc. (NASDAQ:YHOO) begun last trade with a price of $38.76 and throughout the trading session climbed at a high of $39.12. The day-trade ended with -1.96% to $38.61. The stock is going forward to its 52 week low with 17.25% and lagging behind from its 52 week high price with -26.62%. YHOO last month stock price volatility remained 1.74%.
Biopharmaceutical company, Horizon Pharma plc (NASDAQ:HZNP) released that it has filed patent infringement court cases in the U.S. District Court for the District of New Jersey associated to Abbreviated New Drug Applications or ANDA filed with the U.S. FDA to market a generic version of Pennsaid or diclofenac sodium topical solution 2% w/w. The lawsuit was filed against Actavis Laboratories UT, Actavis, and Allergan plc, as well as Amneal Pharmaceuticals, LLC, IGI Laboratories, Lupin Ltd. and Lupin Pharmaceuticals, as well as Taro Pharmaceuticals USA, Inc. and Taro Pharmaceutical Industries, Ltd. Horizon Pharma plc (NASDAQ:HZNP) stock price closed at $34.54 with the total traded volume of 3.09 Million shares. Its price to sales ratio ended at 14.90. Its market capitalization is 5.34 Billion. The stock owned by the Financial Institutions was 71.60% while by insiders was 0.20%.
Allergan Inc. (NYSE:AGN) and Oculeve, reported that they have signed into an contract under which Allergan will purchase Oculeve in an all-cash transaction. Allergan will acquire Oculeve for a $125 million upfront payment and commercialization milestone payments related to Oculeve’s lead development program OD-01. The agreement also includes the acquisition of an additional earlier-stage dry eye device development program. Allergan said its 2015 EPS forecast provided on May 11, 2015 is unchanged as a result of the acquisition. Allergan Inc. (NYSE:AGN) has the market capitalization of 120.36 Billion. Shares of firm moved down -0.26% to close at $306.70 with the total traded volume of 1.54 Million. The firm has current ratio of 1.40 for the most recent quarter.